Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 123-128

  Huang, Xiao Jun ^a   Zhao, Jie ^a   Zhao, Xiang Yu ^a   Chang, Ying Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Combination; Graft versus host disease; Graft versus leukemia effect; Recombinant human granulocyte colony stimulating factor; Recombinant human interleukin 11; T cell

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POLARITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; DRUG POTENTIATION; ERYTHROLEUKEMIA; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; MONOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; INTERLEUKIN-11; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 55049131625     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.009     Document Type: Article

References (27)

1. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344 (2001) 175-181
2. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38 (2006) 291-297
3. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107 (2006) 3065-3073
4. Cavazzana-Calvo M., Andre-Schmutz I., Hacein-Bey-Abina S., Bensoussan D., Le Deist F., and Fischer A. Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin Hematol 39 (2002) 32-40
5. Chang Y.J., Zhao X.Y., and Huang X.J. Effect of granulocyte colony-stimulating factor on immunological regulation and its application in allogeniec hematopoietic stem cell transplantation-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15 (2007) 1121-1125
6. Morris E.S., MacDonald K.P., and Hill G.R. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 107 (2006) 3430-3435
7. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23 (2005) 5074-5087
8. Morris E.S., MacDonald K.P., Rowe V., et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 103 (2004) 3573-3581
9. Rutella S., Zavala F., Danese S., Kared H., and Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 175 (2005) 7085-7091
10. Klangsinsirikul P., and Russell N.H. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 30 (2002) 495-501
11. Jun H.X., Jun C.Y., and Yu Z.X. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 89 (2004) 1517-1524
12. Chang Y.J., Zhao X.Y., and Huang X.J. Peripheral blood T cell immuno-tolerance in PBSCT donors induced by rhG-CSF in vivo. Zhongguo Shi Yan Xue Ye Xue Za Zhi 13 (2005) 16-19
13. Bozza M., Bliss J.L., Dorner A.J., and Trepicchio W.L. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. J Interferon Cytokine Res 21 (2001) 21-30
14. Hartung G., Zeis M., Glass B., et al. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model. Bone Marrow Transplant 32 (2003) 49-56
15. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 104 (1999) 317-325
16. Hill G.R., Cooke K.R., Teshima T., et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 102 (1998) 115-123
17. Zhao J., Zhao X.Y., and Huang X.J. Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation. Zhonghua Yi Xue Za Zhi 85 (2005) 2497-2502
18. Zhao J., Zhao X.Y., and Huang X.J. Comparative study on the treatment effects with rhIL-11 and rhG-CSF in combination or alone on immune function. Zhonghua Xue Ye Xue Za Zhi 26 (2005) 469-472
19. Fowler D.H., Kurasawa K., Smith R., Eckhaus M.A., and Gress R.E. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84 (1994) 3540-3549
20. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88 (1996) 3230-3239
21. Krenger W., Cooke K.R., Crawford J.M., et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 62 (1996) 1278-1285
22. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
23. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100 (2003) 2742-2747
24. Montagna D., Maccario R., Locatelli F., et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 108 (2006) 3843-3850
25. Schmaltz C., Alpdogan O., Horndasch K.J., et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97 (2001) 2886-2895
26. Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., and Allison J.P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356 (1992) 607-609
27. Koehler H., Kofler D., Hombach A., and Abken H. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res 67 (2007) 2265-2273